Initial identification of new investigational drugs for the treatment of epilepsy is commonly conducted in well‐established mouse acute and chronic seizure models: for example, maximal electroshock (MES), 6 Hz, and corneal kindling. Comparison of the median effective dose (ED50) of approved antiseizure drugs (ASDs) vs investigational agents in these models provides evidence of their potential for clinical efficacy. Inbred and outbred mouse strains exhibit differential seizure susceptibility. However, few comparisons exist of the ED50 or median behaviorally impairing dose (TD50) of prototype ASDs in these models in inbred C57Bl/6 vs outbred CF‐1 mice, both of which are often used for ASD discovery.

中文翻译：

---

远交与近交小鼠的已建立和新型药物发现癫痫模型中的抗癫痫药物疗效和耐受性


用于治疗癫痫的新研究药物的初步鉴定通常在完善的小鼠急性和慢性癫痫模型中进行：例如最大电击（MES）、6 Hz 和角膜点燃。在这些模型中比较已批准的抗癫痫药物 (ASD) 与研究药物的中位有效剂量 (ED50)，提供了其临床疗效潜力的证据。近交系和远交系小鼠表现出不同的癫痫易感性。然而，在近交 C57Bl/6 与远交 CF-1 小鼠模型中，原型 ASD 的 ED50 或中位行为损害剂量 (TD50) 几乎没有比较，这两种小鼠都经常用于 ASD 发现。